Invossa Fallout: Call For Review Of All Korea-Approved Cell Therapies
Although the big decision has been made for Invossa in Korea, things have not settled down and there have been calls for re-examination of all approved cell therapies, the recall of R&D grants provided to Kolon and expansion of a probe into the company’s leadership and government officials.
You may also be interested in...
Novartis CEO Explains Delay In Telling US FDA About Zolgensma Data Fraud: We Wanted To Understand It First
Novartis is in the process of "exiting" the "small number" of scientists involved in the fraud, CEO Narasimhan says.
Gene therapy should remain on the market, FDA says, but Novartis could face civil or criminal penalties. Firm knew of problems before approval.
After selecting the bio-health sector as one of three major industries to nurture, South Korea unveils new strategy to triple the industry’s global market share and improve regulations in line with global standards, with a focus on the pharma and medical device sectors. While industry supports the move, some uncertainties could slow the government’s efforts.